NAME OF THE MEDICINE

Domperidone
Domperidone has the following chemical structure.

\[
\text{C}_22\text{H}_24\text{ClN}_5\text{O}_2 \quad \text{MW: 425.9} \quad \text{CAS Registry No.: 57808-66-9}
\]

The chemical name for domperidone is 5-Chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]-piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.

DESCRIPTION
Domperidone is a white to slightly beige coloured powder; it is freely soluble in 1.0M lactic acid, soluble in 1.0M citric acid, slightly soluble in ethanol and practically insoluble in water.

Inactive ingredients: lactose, maize starch, microcrystalline cellulose, pregelatinised potato starch, povidone, magnesium stearate, hydrogenated cottonseed oil, sodium lauryl sulfate, and hypromellose.

PHARMACOLOGY
Pharmacodynamics
Mechanism of Action
MOTILIUM is a dopamine antagonist with antiemetic properties similar to those of metoclopramide and certain neuroleptic drugs. Unlike these drugs, however, domperidone does not readily cross the blood-brain barrier. It seldom causes extra-pyramidal side effects, but does cause a rise in prolactin levels. Its antiemetic effect may be due to a combination of peripheral (gastrokinetic) effects and antagonism of central dopamine receptors in the chemo-receptor trigger zone, which lies in the area postrema and is regarded as being outside the blood brain barrier. Animal studies have shown that domperidone has no effect on plasma concentrations of homovanillic acid, a metabolite of dopamine. It also antagonises the behavioural effects of dopamine much more effectively when administered intracerebrally than when given systemically. These findings, together with the low concentrations found in the brain, indicate a predominantly peripheral effect of domperidone on dopamine receptors.

Studies in humans have shown intravenous and oral domperidone to: increase the duration of antral and duodenal contractions; increase the gastric emptying of liquids and semi solids in healthy subjects and in patients in whom it was delayed; increase lower oesophageal sphincter pressure in healthy subjects. MOTILIUM has no effect on gastric secretion.
Effect on QT/QTC Interval and Cardiac Electrophysiology
In accordance with ICH—E14 guidelines, a thorough QT study was performed in healthy subjects. This study included a placebo, active comparator and positive control and was conducted using recommended therapeutic doses (10 or 20 mg administered 4 times a day). This study found a maximal difference of QTc between domperidone and placebo in LS-means in the change from baseline was 3.4 msec for 20 mg domperidone administered 4 times a day on Day 4, and the 2-sided 90% CI (1.0 - 5.9 msec) did not exceed 10 msec. The QT prolongation observed in this study when domperidone was administered according to the recommended dosing is not clinically relevant.

Pharmacokinetics
Absorption
Domperidone is rapidly absorbed following intramuscular and oral administration with peak plasma concentrations occurring at approximately 10 and 30 minutes, respectively.

Systemic bioavailability of intramuscular domperidone is about 83% whereas that of oral domperidone is 13 to 17%. The low oral bioavailability is probably due to 'first-pass' gut wall and hepatic metabolism. Oral bioavailability is decreased by prior administration of cimetidine or sodium bicarbonate. The time of peak absorption is slightly delayed and the AUC somewhat increased when the oral drug is taken after a meal.

Distribution
Oral domperidone does not appear to accumulate or induce its own metabolism; a peak plasma level after 90 minutes of 21 ng/mL after two weeks oral administration of 30 mg per day was almost the same as that of 18 ng/mL after the first dose. Domperidone is 91-93% bound to plasma proteins.

Distribution studies with radiolabelled drug in animals have shown wide tissue distribution with low brain concentration. Small amounts of drug cross the placenta in rats and the drug is excreted in the breast milk of this species.

Metabolism
Domperidone undergoes rapid and extensive hepatic metabolism by hydroxylation and N-dealkylation. In vitro metabolism experiments with diagnostic inhibitors revealed that CYP3A4 is a major form of cytochrome P-450 involved in the N-dealkylation of domperidone, whereas CYP3A4, CYP1A2 and CYP2E1 are involved in domperidone aromatic hydroxylation (see INTERACTIONS).

Elimination
Urinary and faecal excretion amounts to 31 and 66%, respectively, of the oral dose. The proportion of the drug excreted unchanged is small (approximately 1% of urinary excretion and 10% of faecal excretion).

The plasma half-life after a single oral dose is 7-9 hours in healthy subjects but is prolonged in patients with severe renal insufficiency.

Special Populations
Hepatic Impairment
MOTILIUM is contraindicated in patients with moderate or severe hepatic impairment (see CONTRAINDICATIONS). In subjects with mild hepatic impairment (Pugh score 5 to 6, Child-Pugh rating A), limited data indicate that the pharmacokinetics of domperidone are not significantly altered. In subjects with moderate hepatic impairment (Pugh score 7 to 9, Child-Pugh rating B), the AUC, Cmax and terminal elimination half-life of domperidone were substantially increased; the unbound fraction of domperidone was increased by 25%. Subjects with severe hepatic impairment were not studied (see CONTRAINDICATIONS).
Renal Impairment
In subjects with severe renal insufficiency (serum creatinine > 6 mg/100 mL, i.e., > 0.6 mmol/L) the half-life of domperidone is increased from 7.4 to 20.8 hours, but plasma drug levels are lower than in subjects with normal renal function. Very little unchanged drug (approximately 1%) is excreted via the kidneys (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Paediatric Patients
NO PHARMACOKINETICS DATA ARE AVAILABLE IN THIS POPULATION.

INDICATIONS
MOTILIUM is indicated for the short-term treatment in adults of:

- Symptoms associated with idiopathic or diabetic gastroparesis (once control of diabetes has been established by diet and/or insulin, an attempt should be made to discontinue MOTILIUM).

- Intractable nausea and vomiting from any cause.

CONTRAINDICATIONS
*MOTILIUM is contraindicated in the following situations:

- In patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances underlying cardiac diseases such as congestive heart failure

- Co-administration with medicines that prolong the QTc interval (see PRECAUTIONS and INTERACTIONS WITH OTHER MEDICINES)

- Co-administration with potent CYP3A4 inhibitors (see PRECAUTIONS and INTERACTIONS WITH OTHER MEDICINES)

- Known hypersensitivity to domperidone or any of the excipients

- Prolactin-releasing pituitary tumour (prolactinoma).

- Whenever stimulation of gastric motility might be dangerous, e.g. in the presence of gastro-intestinal haemorrhage, mechanical obstruction or perforation.

- In patients with moderate or severe hepatic impairment (see Pharmacokinetics).

PRECAUTIONS
The film-coated tablets contain lactose and may be unsuitable for patients with lactose intolerance, galactosemia or glucose/galactose malabsorption.

Antacids or antisecretory drugs should not be taken simultaneously with MOTILIUM since they reduce its oral bioavailability of domperidone (see INTERACTIONS WITH OTHER MEDICINES). When used concomitantly, MOTILIUM should be taken before meals and antacids or antisecretory agents after meals.

Cardiac effects
MOTILIUM is associated with an increased risk of sudden cardiac death of approximately 4 per 1000 years compared with no use of medication. This risk is increased in patients aged over 60 years or who have cardiac disease or diabetes. The risk is also increased with MOTILIUM doses > 30 mg daily and when taken in combination with medicines that prolong the QT interval and medicines that inhibit CYP3A4.

*Concurrent use of MOTILIUM with medicines that prolong the QTc interval is contraindicated. Concurrent use of MOTILIUM with medicines that are potent inhibitors of CYP3A4 is contraindicated (see CONTRAINDICATIONS and INTERACTIONS WITH OTHER MEDICINES).
MOTILIUM (170928) PPI

*Concurrent use of MOTILIUM with medicines that are moderate inhibitors of CYP3A4 should be avoided. Long term use of MOTILIUM should be avoided.* The lowest dose needed to alleviate symptoms should be taken for the shortest period of time.

MOTILIUM should be used with caution in older patients or those with current or a history of cardiac disease.

In a case-control study by van Noord et al (2010), the odds of sudden cardiac death with current domperidone use (10 cases) were two-fold higher than the odds of sudden cardiac death in matched controls from the general population (adjusted odds ratio, 1.99 [95% CI, 0.80 - 4.96]). The adjusted odds ratio for sudden cardiac death in current users of a dose higher than 30 mg daily, relative to matched controls from the general population, was 11.4 (95% CI, 1.99 - 65.2) based on 4 identified cases. In a larger case-control study by Johannes et al (2010), the adjusted odds ratio for the composite of sudden cardiac death and serious ventricular arrhythmias was 1.44 (95% CI, 1.12 - 1.86) for current domperidone users relative to current proton-pump inhibitor users.

A population based, case-control study nested in a cohort of 681,104 patients with at least one recorded prescription for domperidone, any proton pump inhibitor medication, or metoclopramide found 90 cases of out-of-hospital Sudden Cardiac Death (SCD) with current domperidone use.

The incidence rate of SCD per 1,000 person-years with current usage of domperidone was 4.47 (95% CI, 43.59 – 5.49). This was higher than that for during person-time with no use of any of the study medications (0. 87; 95% CI, 0.82 – 0.92).

After adjusting for demographic characteristics, medical conditions, medications, and other potentially confounding factors, the point estimate for current use of domperidone compared with non-use of study medications was OR, 1.71 (95% CI, 0.92 – 3.18).

In all of the medication group strata, the incidence increased with age, was higher in men than women, and was higher in those with diabetes than without.

With exposure to domperidone, the highest OR for SCD was with current exposure to only domperidone for 8-14 days (adjusted OR, 7.77; 95% CI, 1.70 – 35.53). The adjusted OR was 1.69 (95% CI, 0.38 - 7.57) for exposure of ≤7 days and 1.12 (95% CI, 0.50 – 2.53) for durations of ≥15 days. The risk of SCD compared with no exposure was highest for those prescribed >30 mg/day (adjusted OR, 3.20; 95% CI, 0.59 – 17.34).

When domperidone was taken concomitantly with any QTc prolonging agent associated with torsade de pointes the risk of SCD increased from an adjusted OR of 1.64 (95% CI, 0.73 – 3.72) to 4.95 (95% CI, 0.84 – 29.07).

Electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia) and bradycardia are known to be conditions increasing the proarrythmic risk.

Treatment with MOTILIUM should be stopped if signs or symptoms occur that may be associated with cardiac arrhythmia.

**Paediatric Use**
MOTILIUM should not be used in children.

**Prolactin levels**
There are limited safety data in long-term use (i.e. beyond six months) of MOTILIUM. However, it has been shown to produce an increase in plasma prolactin. The raised level persists with chronic
administration but falls to normal on discontinuing the drug (see ADVERSE EFFECTS). During
oral administration of 30 mg daily for two weeks the plasma prolactin level measured 90 minutes
after drug intake remained fairly constant at 25 ng/mL in males (normal value was 5 ng/mL) whilst
in females the level of 117 ng/mL after the first dose decreased to 56 ng/mL after 14 doses
(pretreatment normal value was 9 ng/mL).

Tissue culture experiments indicate that approximately one-third of human breast cancers are
prolactin dependent in vitro, a factor of potential importance if the prescription of MOTILUM is
contemplated in a patient with a past history of breast cancer.

Endocrine disturbances such as galactorrhoea, amenorrhoea, gynaecomastia and impotence
have been reported with drugs which stimulate prolactin release. The clinical significance of
elevated serum prolactin levels is unknown for most patients. An increase in mammary
neoplasms has been found in rodents after chronic administration of MOTILUM and other
prolactin stimulating drugs. Neither clinical studies nor epidemiologic studies conducted to date
have shown an association between chronic administration of these drugs and mammary
tumorigenesis.

MOTILUM does not affect plasma growth hormone or aldosterone.

Despite the lack of penetration of the blood-brain barrier, the possibility that extrapyramidal
symptoms may occur in very rare instances after long-term use of domperidone, should be
considered.

Renal Impairment – since the elimination half-life of domperidone is prolonged in severe renal
impairment, on repeated administration the dosing frequency of MOTILUM should be reduced to
once or twice daily, depending on the severity of the impairment, and the dose may need to be
reduced. Such patients on prolonged therapy should be reviewed regularly (see
Pharmacokinetics and DOSAGE AND ADMINISTRATION).

Use in Pregnancy – Category B2 - Small amounts of MOTILUM have been found in rat foetal
tissues. Reproduction studies were performed in rats with daily doses of MOTILUM up to
160 mg/kg orally and 40 mg/kg intravenously and in rabbits with daily doses up to 40 mg/kg orally
and 1.25 mg/kg intravenously. There was no evidence of drug related dysmorphogenesis. There
are however no adequate and well controlled studies in pregnant women. The potential risk for
humans is unknown. Because animal studies are not always predictive of human response and
there are limited post-marketing data on the use of domperidone in pregnant women, this drug
should be used during pregnancy only if clearly needed.

Use in Lactation –. The amount of domperidone that could be ingested by an infant through
breast milk is extremely low. The maximal relative infant dose (%) is estimated to be about 0.1%
of the maternal weight-adjusted dosage. It is not known whether this is harmful to the newborn.
Therefore breast-feeding is not recommended for women who are taking MOTILUM.

Effects on Ability to Drive and Use Machines
Dizziness and somnolence have been observed following use of domperidone (see Adverse
Effects). Therefore, patients should be advised not to drive or use machinery or engage in other
activities requiring mental alertness and coordination until they have established how MOTILUM
affects them.

Genotoxicity
No relevant data are available.

Carcinogenicity
See Prolactin levels.
**Effects on fertility**
No relevant data are available.

**INTERACTIONS WITH OTHER MEDICINES**

*Medicines that prolong the QTc interval*

Co-administration with medicines that prolong the QTc interval is contraindicated due to an increased risk of sudden cardiac death shown in post-market studies (see CONTRAINDICATIONS and PRECAUTIONS).

Examples of QTc-prolonging medicines include:
- anti arrhythmics class IA (e.g. disopyramide)
- anti arrhythmics class III (e.g. amiodarone*, dronedarone, sotalol)
- some antipsychotics (e.g. haloperidol)
- some antidepressants (e.g. citalopram, escitalopram)
- some antibiotics (e.g. erythromycin*, clarithromycin*, levofloxacin, moxifloxacin)
- some antifungal agents (e.g. pentamidine)
- some antimalarial agents (e.g. lumefantrine)
- some azole antifungals, (e.g. itraconazole*, ketoconazole*, voriconazole*, fluconazole*)
- some calcium antagonists, (e.g. diltiazem*, verapamil*)
- some gastrointestinal agents (e.g. prucalopride, granisetron, ondansetron)
- certain HIV protease inhibitors (e.g. atazanavir*, fosamprenavir*, indinavir*, ritonavir*, saquinavir*)
- some antineoplastic agents (e.g. toremifene, vandetanib)
- others (e.g. aprepitant* and methadone)

*also potent CYP3A4 inhibitors (see CONTRAINDICATIONS)*

**Potent CYP3A4 inhibitors**
The main metabolic pathway of domperidone is through the cytochrome P450 isoenzyme CYP3A4. *In vitro* and human data show that the concomitant use of drugs that significantly inhibit this enzyme may result in increased plasma levels of domperidone.

*Concurrent use of MOTI LiUM with medicines that are potent inhibitors of CYP3A4 is contraindicated due to an increased risk of sudden cardiac death shown in postmarket studies (see CONTRAINDICATIONS and PRECAUTIONS).*

Examples of potent CYP3A4 inhibitors include:
- Azole antifungals, such as fluconazole^, itraconazole^, ketoconazole^ and voriconazole^;
- Macrolide antibiotics, such as clarithromycin^ and erythromycin^;
- HIV protease inhibitors, such as amprenavir^, atazanavir^, fosamprenavir^, indinavir^, nelfinavir^, ritonavir^ and saquinavir^;
- Calcium antagonists, such as diltiazem^ and verapamil^;
- Amiodarone^;
- Aprepitant^;
- Telithromycin^;
- Nefazodone

^also prolong the QTc interval; (see CONTRAINDICATIONS)

Separate pharmacokinetic/pharmacodynamic interaction studies with oral ketoconazole or oral erythromycin in healthy subjects confirmed domperidone C_max increases <3 fold under maximal CYP3A4 inhibition by these drugs.
In these studies, domperidone monotherapy at 10 mg four times daily resulted in increases in mean QTc of 1.6 msec (ketoconazole study) and 2.5 msec (erythromycin study), while ketoconazole monotherapy (200 mg twice daily) and erythromycin monotherapy (500 mg three times daily) led to increases in mean QTc of 3.8 and 4.9 msec, respectively, over the observation period. With the combination of domperidone 10 mg four times daily and ketoconazole 200 mg twice daily, a mean QTc prolongation of 9.8 msec was seen over the observation period, with changes at individual time points ranging from 1.2 to 17.5 msec. With the combination of domperidone 10 mg four times daily and erythromycin 500 mg three times daily, mean QTc over the observation period was prolonged by 9.9 msec, with changes at individual time points ranging from 1.6 to 14.3 msec. Both the C\text{max} and AUC of domperidone at steady state were increased approximately three-fold in each of these interaction studies (see CONTRAINDICATIONS).

The contribution of increased plasma concentrations of domperidone to the observed effect on QTc is not known.

**Moderate CYP3A4 inhibitors**

Concurrent use of MOTILIUM with medicines that are moderate inhibitors of CYP3A4 should be avoided due to an increased risk of sudden cardiac death shown in postmarket studies (see PRECAUTIONS).

**Miscellaneous Interactions**

Antacids or antisecretory drugs should not be taken simultaneously with MOTILIUM since they reduce its oral bioavailability (i.e., they should be taken after meals and not before meals) (see PRECAUTIONS). Dosing with these agents should be separated from dosing with MOTILIUM by at least 2 hours.

Concomitant administration of anticholinergic drugs may antagonise the anti-dyspeptics effects of MOTILIUM. If administered prior to atropine, MOTILIUM reduces the relaxant effect of atropine upon the lower oesophageal sphincter, but has no reversing effect if atropine is administered first.

Since MOTILIUM has gastrokinetic effects it could influence the absorption of concomitantly orally administered drugs, particularly those of sustained release or enteric-coated formulations. However, in patients already stabilised on digoxin, paracetamol or haloperidol, concomitant administration of MOTILIUM did not influence the blood levels of these drugs.

MOTILIUM has been used with:
- dopaminergic agonists (bromocriptine, L-dopa) for suppression of unwanted peripheral effects such as digestive disorders, nausea and vomiting, without affecting their central activity.

**ADVERSE EFFECTS**

**Clinical Trial Data**

The safety of MOTILIUM was evaluated in 1221 patients with gastroparesis, or symptoms of it in 45 clinical trials included in the safety database. All patients were \( \geq 15 \) years old and received at least one dose of oral MOTILIUM (domperidone base). Slightly fewer than one-half (553/1221) of patients were diabetic. The median total daily dose was 80 mg (range 10 to 160 mg), with 230 patients receiving a dose greater than 80 mg. Median duration of exposure was 56 days (range 1 to 2248 days).

Adverse Reactions (ARs) - reported by \( \geq 1\% \) of patients treated with domperidone in these 45 clinical trials are shown in Table 1.
Table 1.  Adverse Reactions Reported by ≥ 1% of Domperidone - Treated Patients in 45 Clinical Trials

<table>
<thead>
<tr>
<th>System/Organ Class</th>
<th>Adverse Reaction</th>
<th>Domperidone (n=1221) %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Psychiatric Disorders</strong></td>
<td>Depression</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>Anxiety</td>
<td>1.6</td>
</tr>
<tr>
<td></td>
<td>Libido Decreased/Loss of Libido</td>
<td>1.5</td>
</tr>
<tr>
<td><strong>Nervous System Disorders</strong></td>
<td>Headache</td>
<td>5.6</td>
</tr>
<tr>
<td></td>
<td>Somnolence</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>Akathisia</td>
<td>1.0</td>
</tr>
<tr>
<td><strong>Gastrointestinal Disorders</strong></td>
<td>Diarrhoea</td>
<td>5.2</td>
</tr>
<tr>
<td><strong>Skin and Subcutaneous Tissue Disorders</strong></td>
<td>Rash</td>
<td>2.8</td>
</tr>
<tr>
<td></td>
<td>Pruritus</td>
<td>1.7</td>
</tr>
<tr>
<td><strong>Reproductive System and Breast Disorders</strong></td>
<td>Breast Enlargement/Gynaecomastia</td>
<td>5.3</td>
</tr>
<tr>
<td></td>
<td>Breast Tenderness</td>
<td>4.4</td>
</tr>
<tr>
<td></td>
<td>Galactorrhoea</td>
<td>3.3</td>
</tr>
<tr>
<td></td>
<td>Amenorrhoe</td>
<td>2.9</td>
</tr>
<tr>
<td></td>
<td>Breast Pain</td>
<td>2.3</td>
</tr>
<tr>
<td></td>
<td>Menstruation Irregular</td>
<td>2.0</td>
</tr>
<tr>
<td></td>
<td>Lactation Disorder</td>
<td>1.6</td>
</tr>
<tr>
<td><strong>General Disorders and Administration Site Conditions</strong></td>
<td>Asthenia</td>
<td>1.9</td>
</tr>
</tbody>
</table>

ARs that occurred in < 1% of Domperidone-treated patients in the 45 clinical trials (n=1221) are listed below in Table 2.

Table 2.  Adverse Reactions Reported by < 1% of Domperidone - Treated Patients in 45 Clinical Trials

<table>
<thead>
<tr>
<th>System/Organ Class</th>
<th>Adverse Reaction</th>
<th>Domperidone(n=1221) %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immune System Disorders</strong></td>
<td>Hypersensitivity</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>Skin and Subcutaneous Tissue Disorders</strong></td>
<td>Urticaria</td>
<td>0.7</td>
</tr>
<tr>
<td><strong>Reproductive System and Breast Disorders</strong></td>
<td>Breast Discharge</td>
<td>0.8</td>
</tr>
<tr>
<td></td>
<td>Breast Swelling</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Postmarketing Data

The adverse reactions are ranked by frequency, using the following convention:

- Very common: >1/10
- Common: >1/100, <1/10
- Uncommon: >1/1000, <1/100
- Rare: >1/10000, <1/1000
- Very rare: <1/10000 including isolated reports
**Immune system disorder:**
*Very rare:* anaphylactic reactions including anaphylactic shock; angioneurotic oedema; allergic reaction

**Endocrine disorder**
*Uncommon:* increased prolactin levels

**Psychiatric system disorders**
*Uncommon:* nervousness

*Very rare:* agitation

**Nervous system disorders**
*Common:* dry mouth; headache

*Uncommon:* insomnia; dizziness; thirst; lethargy; irritability

*Rare:* extrapyramidal side effects

*Very rare:* convulsion; somnolence

**Gastrointestinal disorders**
*Uncommon:* diarrhoea; regurgitation; appetite disorder; nausea; heartburn; constipation

**Skin and subcutaneous tissue disorders**
*Uncommon:* urticaria; pruritus; rash

**Reproductive system and breast disorders**
*Rare:* galactorrhoea; gynaecomastia; amenorrhoea

**Urinary system disorders**
*Uncommon:* Pollakiuria; dysuria

**Cardiovascular disorders**
*Uncommon:* Oedema; palpitations

*Very rare:* Sudden Cardiac Death*, Serious Ventricular Arrhythmias* (see PRECAUTIONS)

**Musculoskeletal disorders**
*Uncommon:* Muscle spasms; asthenia

**Other**
*Uncommon:* Conjunctivitis; stomatitis; drug intolerance

**Investigations:**
*Uncommon:* liver function test abnormal; cholesterol

*Based on epidemiology data*
During long-term studies with MOTILIUM there have been reports of adverse effects possibly related to increases in serum prolactin (see PRECAUTIONS). These effects include: Gynaecomastia, breast tenderness, swelling of the breasts, irregular menses, amenorrhoea, a decrease or loss of libido, breast secretion and lactation. These effects occurred in patients who received up to 120 mg per day in four divided doses.

Extrapyramidal disorder occurs very rarely, and when seen occurs primarily in young children. (see PRECAUTIONS).

Other central nervous system-related effects of convulsion and agitation also are reported primarily in infants and children.

**DOSAGE AND ADMINISTRATION**

Long-term use and use with medicines that prolong the QT interval or medicines that inhibit CYP3A should be avoided. The lowest dose needed to alleviate symptoms should be taken for the shortest period of time (see Cardiac effects).

MOTILIUM should be taken 15-30 minutes before meals and, if necessary, before retiring. Patients should try to take each dose at the scheduled time. If a scheduled dose is missed, the missed dose should be omitted and the usual dosing schedule resumed. The dose should not be doubled to make up for a missed dose.

**Adults** - 10 mg three times daily. Domperidone should be initiated at the lowest effective dose for the individual situation, which may be adjusted upward with caution to achieve the desired effect. The expected benefit of an increased dose should outweigh the potential risks. Usually, the maximum treatment duration should not exceed one week for the treatment of acute nausea and vomiting. For other indications, the initial duration of treatment is limited to 4 weeks. Patients should undergo a benefit/risk re-analysis if treatment beyond 4 weeks is contemplated.

The maximum daily dose is 30 mg.

Safety and efficacy of MOTILIUM (domperidone) use beyond six months has not been established.

**In patients with severe renal insufficiency** - (creatinine serum > 0.6 mmol/L) the elimination half life of MOTILIUM was increased from 7.4 to 20.8 hours but plasma drug levels were lower than in healthy volunteers. Since very little unchanged drug is excreted via the kidneys, it is unlikely that the dose needs to be adjusted for single acute administration in patients with renal insufficiency. However, on repeated administration, the dosing frequency will need to be reduced to once or twice daily depending on the severity of the impairment, and the dose may need to be reduced. Patients with severe renal impairment on prolonged therapy should be reviewed regularly (see Pharmacokinetics).

**Food** - It is recommended that MOTILIUM be taken 15-30 minutes before meals. If taken after meals absorption of the drug is somewhat delayed. Patients should try to take each dose at the scheduled time. If a scheduled dose is missed, the missed dose should be omitted and the usual dosing schedule resumed. The dose should not be doubled to make up for a missed dose.

**Hepatic impairment** – MOTILIUM is contraindicated for patients with moderate or severe hepatic impairment (see CONTRAINDICATIONS).
OVERDOSAGE

Symptoms and signs
Overdose has been reported primarily in infants and children. Symptoms of overdosage may include agitation, altered consciousness, convulsion, disorientation, somnolence and extrapyramidal reactions.

Treatment
There is no specific antidote to domperidone, but in the event of a large overdose, gastric lavage within one hour of ingestion as well as the administration of activated charcoal may be useful. Anticholinergics, antiparkinson drugs may be useful in controlling extrapyramidal reactions.

The patient should be observed closely and supportive measures employed.

PRESENTATION AND STORAGE CONDITIONS
MOTILIUM 10 mg tablets are white, film coated, circular, normally arched, biconvex tablets, diameter 6.4 mm, one surface debossed with M/10 inscription and the other with JANSSEN. Each tablet contains 10 mg domperidone.

MOTILIUM domperidone 10 mg film coated tablets are supplied in PVC/Aluminium blister packs of 25s, 100s.

Shelf life: 3 years. Store below 30°C.

NAME AND ADDRESS OF SPONSOR
JANSSEN-CILAG Pty Ltd
1-5 Khartoum Road Macquarie Park NSW 2113 Australia

POISON SCHEDULE OF THE MEDICINE
S4 – Prescription Only Medicine

DATE OF FIRST INCLUSION IN THE ARTG: 13 MAY 1992
DATE OF MOST RECENT AMENDMENT: 28-SEP-2017

*Please note changes (presented as *italicised text) in Product Information.